232 results about "Fetus" patented technology

The present invention relates to an incubation system for liquid-based incubation of prematurely born infants, comprising: —an inner chamber forming an amniotic basin comprising amniotic fluid, said basin being configured for holding said infant and being made from a flexible material configured for expanding said inner chamber volume in correspondence with the growth of said infant; —an outer chamber enclosing said inner chamber and comprising a temperature regulation fluid, —a fetal connection port, arranged for connecting with the umbilical cord of said infant, said umbilical cord providing a port in said inner chamber to said infant for providing dialyzation and nutrition compounds to said infant via said umbilical cord; —a fetal control unit, connected to said fetal connection port for control of said dialyzation and control of said provided nutrition by monitoring and controlling one or more of a pressure, flow and temperature thereof; an amniotic fluid circulation unit, arranged for connecting with an inlet / outlet port of said inner chamber and comprising a pump for circulating said amniotic fluid from said inner chamber and through a purification system located outside said inner chamber; and —a temperature regulation fluid control unit, arranged for connecting with an inlet / outlet port of said outer chamber and comprising a pump for circulating said temperature regulation fluid from said outer chamber and through a heat exchanger system located outside said inner chamber.

Compositions, methods, kits, systems, and software are provided for non-invasive prenatal testing for autosomal recessive diseases. Next generation sequencing is used to sequence maternal and fetal DNA isolated from maternal plasma by probe capture. The fetal fraction of the sequencing reads for DNA isolated from maternal plasma is estimated by counting single nucleotide polymorphisms (SNPs) for which an allele is detected that is present in the paternal haplotype but absent in the maternal haplotype, based on the assumption that SNPs having a paternal allele belong to the fetal DNA. The fetal fraction is bioinformatically enriched by excluding sequencing reads over a specified length via in-silico size selection, which increases fetal genotype prediction accuracy. Parental haplotype information together with the read ratios observed at the linked SNPs is used to predict the fetal genotype at a site of a mutation linked to the autosomal recessive disease.

The invention provides a non-invasive fetal trisomy 21 syndrome prenatal screening kit based on digital PCR, and relates to the technical field of fetal trisomy 21 syndrome screening, according to a method for enriching fetal cfDNA in pregnant woman plasma, SPRIselect magnetic beads with low enrichment multiple and silicon hydroxyl magnetic beads are combined for use, and under a certain dosage, the recovery rate of fetal cfDNA short fragments reaches 95%; according to the provided multiple system construction method, positive gDNA and negative gDNA are obtained on the basis of a 21 trisomy positive cell line and a 21 trisomy negative cell line, low-proportion reference substances are prepared and used, internal reference sites and detection sites which are high in detection capacity and stable in detection performance are screened from the beginning, and compared with existing multiple system establishment and verification through direct use of pregnant woman plasma samples, the multiple system construction method has the advantages that the detection efficiency is high, and the detection cost is low. The to-be-detected sample with lower fetal cfDNA content can be stably detected.

The invention discloses a self-adaptive noninvasive fetal electrocardiosignal extraction method based on a logarithmic hyperbolic secant function. The method comprises the following steps: constructing a mother abdomen electrocardiosignal model; based on a self-adaptive filtering framework, inputting a chest electrocardiosignal MECG of the mother as a reference signal and an abdomen signal AECG as an expected signal, and calculating filtering output; defining a target function and updating a weight coefficient; the extracted fetal electrocardiosignals are output through Monte Carlo experiment optimization parameter combination; the invention further lays a foundation for long-term real-time monitoring of puerperae and fetuses through portable equipment.

The invention discloses a quality grade and risk identification acquisition method for a prenatal ultrasound key anatomical structure. The method comprises the following steps: firstly, automatically identifying a standard section of a fetus and carrying out pixel-level segmentation on the key anatomical structure; on the basis, indexes such as visibility, orientation consistency and boundary integrity are extracted, a comprehensive quality score is calculated, and corresponding quality grades and risk identifiers are output according to threshold rules, so that an objective, consistent and traceable quality evaluation closed loop is formed, segmentation results are structured into quantitative indexes and graded alarms, and the quality evaluation accuracy is improved. The system can realize automatic evaluation and risk prompt of the standard section quality on the premise of not changing the existing clinical process, and improves the quality control efficiency and consistency.

The invention provides methods for non-invasive prenatal testing that allow for detecting risk of chromosomal and subchromosomal abnormalities, including but not limited to aneuploidies, microdeletions and microduplications, insertions, translocations, inversions and small-size mutations including point mutations and mutational signatures. The methods of the invention utilize a pool of TArget Capture Sequences (TACS) to enrich for sequences of interest in a mixed sample containing both maternal and fetal DNA, followed by massive parallel sequencing and statistical analysis of the enriched population to thereby detect the risk of a genetic abnormality in the fetal DNA. Kits for carrying out the methods of the invention are also provided.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The invention provides methods for assessment of fetal DNA samples using target-enriched multiplexed parallel analysis. The methods of the invention utilize TArget Capture Sequences (TACS) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods can be used with fetal or embryonic DNA samples, for example for detection of the presence of genetic abnormalities, e.g., for purposes of IVF Pre-implantation Genetic Screening (PGS) and Diagnosis (PGD). Kits for carrying out the methods of the invention are also provided.

Provided herein are computer-implemented methods for assigning maternal or fetal origin to one or more genetic variations in cell-free DNA (cfDNA) of a sample from a pregnant mammal, preferably a pregnant human, it uses a probabilistic model for assigning maternal or fetal origin to genetic variations in DNA from a sample obtained from a pregnant mammal, where the model assigns maternal or fetal origin based on a combination of fetal fraction and DNA fragment size.

The invention relates to the field of image processing, in particular to a fetal hydrocephalus three-dimensional reconstruction and operation planning method based on multiple modalities, which comprises the following steps: obtaining key points and ventricular postures in a three-dimensional point cloud during each three-dimensional reconstruction, predicting the ventricular postures during the next three-dimensional reconstruction, and obtaining prediction residual errors; historical three-dimensional reconstruction key points are clustered based on prediction residual errors to obtain all categories, and when three-dimensional reconstruction is carried out again, the obtained three-dimensional point clouds are further deleted and added based on the categories. According to the invention, errors in a matching fusion process and errors in a prediction process during three-dimensional reconstruction are avoided, and the accuracy of a three-dimensional reconstruction result is improved.

The application relates to the technical field of data management control, and particularly discloses a data management control method and system based on a maternal and infant one-stop learning cloud platform, which comprises the following steps: based on real-time collected maternal and infant physiological data, maternal and infant historical health records and user learning behavior data, a multi-modal maternal and infant user portrait containing dynamic health state labels and dynamic learning ability labels is constructed; based on multi-modal maternal and infant user portraits of all maternal and infant users, multi-dimensional health horizontal comparison factors of pregnant women and fetuses or infants in each maternal and infant user under each division attribute and each division level are determined, and maternal and infant health deviations of each maternal and infant user are analyzed; based on the multi-dimensional health horizontal comparison factors of the pregnant women and the fetuses or the infants in each maternal and infant user under each division attribute and each division level and the maternal and infant health deviations, intelligent adaptation of multiple services is driven; and a closed loop from health deviation to education content, health plan and deviation improvement is formed.

Disclosed herein is deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure. Use of deuterated buprenorphine prevents or reduces exposure of the fetus to opioids used by the mother. Use of deuterated buprenorphine may prevent or reduces exposure of the fetus to harmful metabolites of buprenorphine.

The application provides a fetal posture evaluation method, an ultrasonic imaging method and an ultrasonic imaging system. The fetal posture evaluation method comprises the following steps: acquiring three-dimensional ultrasonic data of an early-pregnancy fetus; acquiring a head region and a body region of the early-pregnancy fetus in the three-dimensional ultrasonic data; evaluating a posture of the early-pregnancy fetus based on a relative positional relationship between the head region and the body region of the early-pregnancy fetus, to obtain a posture evaluation result; and displaying the posture evaluation result. The method can facilitate a doctor to observe the posture of the fetus and quickly learn whether the posture of the early-pregnancy fetus is in a natural posture.

The present disclosure provides compositions and methods for inducing an immune response in a fetus or newborn. In particular, the disclosure provides compositions and methods for transamniotic administration of a polynucleotide encoding a pathogen antigen.

A wearable birthing simulator and method of operating thereof are disclosed. The simulator includes a housing that is securable to a subject and the housing defines an opening. Positioned within the housing is a uterus simulator and a removable fetal model contained therein. Coupled to the uterus simulator is a birth canal simulator. A birthing device comprises an actuator assembly in communication with the controller for automatically moving the fetal model towards the birth canal simulator. One or more sensors are mounted to the housing and are electrically connected to the controller for detecting movement of the fetal model by the birthing device. The feedback device is configured to provide the haptic feedback to the subject in response the movement of the fetal model toward the birth canal simulator. The disclosed simulator may be used to simulate a variety of childbirth scenarios.

The present application relates to devices for monitoring pregnancy or labor. In one embodiment, the device includes an electromyography (EMG) sensor having two or more EMG electrodes that monitor fetal or maternal activity during pregnancy or labor, and one or more position sensors that monitor the relative positioning of the two or more EMG electrodes during fetal or maternal activity. In one embodiment, the device includes a monitoring apparatus that is placed on a body and has a plurality of sensors integrated into the monitoring apparatus, the plurality of sensors including at least a first sensor configured to detect a first type of signal from the body indicative of a first type of fetal or maternal activity during pregnancy or labor, and a second sensor configured to detect a second type of signal from the body different from the first type of signal also indicative of the first type of fetal or maternal activity during pregnancy or labor.

The present invention relates to the field of biotechnology and relates to a hydatidiform mole genetic typing detection system, kit, and application. The composite amplification system includes 20 pairs of primers capable of simultaneously amplifying 20 genomic loci, and the primer sequences for each of the 20 loci are disclosed. The kit incorporates a UDG enzyme anti-contamination system to digest any amplification products containing uracil prior to PCR amplification, thereby preventing product contamination. These loci possess high individual recognition power and high polymorphic information content, enabling effective and accurate detection of STR polymorphisms, detection of maternal and fetal loci typing, and, through comparison, determination of fetal hydatidiform mole status.

This invention discloses a method for paternity testing using homozygous loci, belonging to the field of paternity testing technology. The method includes: S101: sequencing the pregnant woman's cell-free DNA sample S and the father's DNA sample F, and genotyping S and F based on sequencing depth; S102: calculating the inefficiency P of the two samples based on the genotyping results. 无 or inefficient P 无 With efficiency P 有 The ratio is used to perform paternity testing; the effectiveness P 有 The effective loci represent the proportion of the homozygous loci in the set X of opposite homozygous loci. Effective loci are those in S that conform to the set X of opposite homozygous loci and can detect fetal signals. Loci in S and F are selected according to Formula I to form the set X of opposite homozygous loci; inefficiency P 无 The percentage of invalid loci in the same homozygous locus set X' is defined as the proportion of invalid loci in S that conform to the same homozygous locus set X' and can detect fetal signals. Loci in S and F are selected according to Formula II to form the same homozygous locus set X'.

The invention provides a method for judging a sib relationship through DNA of a born child and cfDNA of a fetus, and belongs to the technical field of biological identification. According to the non-invasive prenatal sib relation identification method, the risk of traditional invasive detection on pregnant women and fetuses is remarkably reduced, meanwhile, through a high-sensitivity genetic information analysis technology, the problems of maternal DNA interference and low fetal free DNA concentration are effectively solved, and the non-invasive prenatal sib relation identification method is suitable for clinical application. And high-reliability determination of the genetic relationship between the fetus and the born child under a non-invasive condition is realized. The method not only provides a scientific basis for confirming the complex family relationship, but also can be extensively applied to the fields of legal identification and medical assisted reproduction, fills the blank of non-invasive antenatal sib relationship identification in the prior art, and has wide social value and industrialization potential.

Examples described herein provide a computer-implemented method that includes receiving a non-invasive transabdominal fetal electroencephalogram (TA-fEEG) signal associated with a pregnant subject. The method further includes using the first machine learning model to reduce unwanted noise in the TA-fEEG signal. The method further includes reconstructing a fetal electroencephalogram (fEEG) signal from the TA-fEEG signal using a second machine learning model.

The invention provides a TRPM8 protein mutant and application thereof, relative to an amino acid sequence of a wild type TRPM8 protein, the TRPM8 protein mutant comprises mutation at one or more positions selected from the 825th site, the 864th site, the 891th site, the 897th site, the 915th site, the 917th site, the 925th site, the 927th site, the 928th site, the 932th site, the 945th site, the 946th site and the 948th site. The invention also provides a separated nucleic acid which is used for coding the TRPM8 protein mutant. The invention also provides a vector containing the isolated nucleic acid and a genetically recombinant porcine fetal fibroblast. According to the invention, a key site which can effectively reduce the cold activation level of the pig TRPM8 without influencing other activation functions is screened, and a new material is provided for animal breeding improvement.

The invention relates to a method for increasing the concentration of fetal free DNA in maternal peripheral blood. The method comprises the following steps: S1, extracting free DNA in maternal peripheral blood; s2, performing terminal repair on the free DNA to obtain a terminal repair product; s3, carrying out fragment screening on the terminal repair product to obtain enriched fetal free DNA (Deoxyribose Nucleic Acid); s4, performing linker connection on the enriched fetal free DNA to obtain a linker connection product; s5, carrying out PCR (Polymerase Chain Reaction) amplification on the linker connection product to obtain an amplification product of the fetal free DNA; and S6, purifying and recovering the amplification product of the fetal free DNA to obtain the constructed fetal free DNA library. The invention also relates to the method. According to the method disclosed by the invention, two magnetic bead screening steps are added, so that the fragments less than 143bp in the cfDNA are enriched, and the fetal concentration is increased to 1.5-5 times of that of the non-enriched fragments, so that the detection failure rate, the false positive rate and the false negative rate of NIPT detection of a sample are remarkably reduced, the accuracy of NIPT detection is improved, and a scientific decision basis is favorably provided for pregnant women.

The present invention pertains to a method for determining DNA sequence variation in a fetus from samples of the fetus and parents using a Bayesian framework. The method comprising the following steps: receiving the samples comprise genomic sequence data covering one or more genomic regions of interest in relation to the fetus and the parents; processing the received samples at least in part based on a reference genome; computing a probability of fetal genotypes based on the samples using the Bayesian framework, where the Bayesian framework computes a posterior probability of whether a DNA sequence variant is present in the samples based on a prior probability and a likelihood function; and determining, based on the posterior probability of fetal genotypes, whether the DNA sequence variant is present in the fetus.

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and / or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

The present invention relates to a method for determining the sex of a fetus in an ungulate.

The present application relates to the field of paternity determination, and provides a non-invasive prenatal paternity relationship determination method and system and electronic equipment, the method comprising: obtaining a paternal DNA sample and a pregnant woman's plasma free DNA sample, the pregnant woman's plasma free DNA sample including a fetal DNA sample; performing genomic sequencing on the paternal DNA sample and the pregnant woman's plasma free DNA sample; after genotype filling, determining the paternal genotype and the fetal genotype; calculating the kinship coefficient of the paternal genotype and the fetal genotype; based on the kinship coefficient of the paternal genotype and the fetal genotype and a pre-constructed corresponding relationship between the kinship coefficient and the paternity relationship, determining the paternity relationship between the father and the fetus. The present application solves the defects of low detection efficiency and high technical cost in the related art, and is convenient to operate, completely non-invasive, and does not cause any physiological interference to the pregnant woman and the fetus; the detection can be carried out from the seventh week of pregnancy, and is suitable for precise identification of the biological father of the fetus and unrelated individuals.

Fetal cardiac magnetic resonance (MR) images of a living fetus, within a uterus of a parent of the fetus, can be generated by imaging the fetus within the uterus using a magnetic resonance imaging (MRI) system. Information indicative of fetal cardiac cycles can be derived from MR data obtained by an MRI system while imaging the fetus, the MR data including MR data for the center of k-space. The derived information may be used to differentiate the fetal cardiac cycles from other sources of noise in the MR data such as the parental cardiac cycles.

Massively parallel sequencing of cell-free maternal plasma DNA has recently been demonstrated to be a safe and effective method for screening for fetal chromosomal aneuploidy. Here, we report an improved sequencing method that significantly increases throughput and reduces costs by replacing the laborious sequencing library preparation step with PCR using a single primer pair. Using this method, samples containing as little as 4% trisomy 21 DNA can be readily distinguished from euploid samples.

A composition for treating a patient with a tissue disease or malformity has a composition containing amniotic fluid. The amniotic fluid has a quantity of gender specific amniotic fluid based on a gender of a fetal source. A method of treating a patient with a tissue disease or malformity comprises the steps of: identifying the tissue region to be treated and selecting a location to apply either topically or by injection or inhalation a composition containing amniotic fluid; selecting the composition containing amniotic fluid wherein the amniotic fluid has a quantity of gender specific amniotic fluid based on a gender of a fetal source allowing more specific targeted growth factors to be used for specific disease processes; and applying or injecting the composition at or into the selected location.